Myda Advisors LLC Corvus Pharmaceuticals, Inc. Transaction History

Myda Advisors LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$1.08 - $1.92 $2,372 - $4,218	2,197 Added 3.19%	71,011 $124,000
Q3 2023 Nov 14, 2023	SELL	$1.41 - $2.97 $43,972 - $92,622	-31,186 Reduced 31.19%	68,814 $100,000
Q2 2023 Aug 11, 2023	BUY	$1.0 - $3.86 $100,000 - $386,000	100,000 New	100,000 $229,000
Q4 2021 Feb 11, 2022	SELL	$2.34 - $5.31 $140,400 - $318,600	-60,000 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$1.89 - $8.53 $113,400 - $511,799	60,000 New	60,000 $290,000

30.4M

1.06M

84.3K

Ticker CRVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,553,500
Market Cap $223M
Description
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...

Get notified when there are updates to the investment portfolio of Myda Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Myda Advisors LLC with notifications on news.